Latest news

Adalvo is thrilled to announce the successful launch of Desmopressin in multiple countries across Europe, in collaboration with key strategic partners. Developed based on the reference brand Minirin Melt from Ferring, Desmopressin...

Adalvo is delighted to announce the successful completion of the FED and Fasting Pilot BE Study for Fidaxomicin Film Coated Tablets 200mg. Developed in collaboration with one of our strategic partners,...

Adalvo proudly announces the addition of Alectinib 300, 450, and 600mg tablets to our product list. Our product, being developed based on the reference brand Alecensa 150mg hard capsules, will serve as...

Adalvo is pleased to announce the restart of the DCP procedure for Ethinylestradiol + Drospirenone 0.03 mg/3 mg, with an anticipated approval date in July 2024. Based on the reference brand...

Adalvo proudly announces the addition of Lenvatinib 4mg/ml Oral Solution to our product portfolio. Our product, developed based on the reference brand LENVIMA, serves as a vital treatment for Differentiated Thyroid...

Adalvo is delighted to announce the restart of the DCP procedure for Dalbavancin powder, with an estimated approval date in May 2024. This antibiotic niche product has been developed based on...

Adalvo is pleased to announce the successful Marketing Authorization (MA) approval of Pomalidomide Hard Capsules 1/2/3/4mg in Israel. Our product, based on the reference brand Imnovid, is indicated for the...

Adalvo proudly announces its recent induction into Medicines for Europe, a renowned association advancing the generic pharmaceutical sector.    As a member, Adalvo will play a pivotal role in shaping the future...

Adalvo is delighted to announce the restart of the DCP procedure for Liraglutide 6mg/ml pre-filled pen, with an estimated approval date anticipated in June 2024. As a generic and bioequivalent...

Adalvo stands in solidarity with the global community on Rare Disease Day, today February 29th, reminding us of the profound challenges faced by millions worldwide battling rare diseases, where access to...

Adalvo is pleased to announce positive progress in the registration process for Mirabegron prolonged-release tablets in European markets. This product has been developed in collaboration with one of our strategic partners,...

Adalvo is pleased to announce that Apremilast 10mg, 20mg, and 30mg film-coated tablets has received its first approval in Europe. Having gained approval in December 2023, this positions Adalvo as the...

Adalvo is delighted to announce the successful DCP approval for Lisdexamfetamine Oral Solution 10mg/ml, developed in close collaboration with one of our strategic partners. This product represents a value-added version of Lisdexamfetamine...

Adalvo is pleased to announce the successful DCP approval for Nintedanib 100mg & 150mg Soft Gel Capsules. This product is developed based on two distinguished reference brands, Ofev and Vargatef. Ofev is indicated for...

Adalvo is proud to announce the successful launch of Desmopressin Sublingual Tablets in France, solidifying our position as the first generic to introduce this innovative medication in the European Union. This accomplishment...

Adalvo is delighted to announce a significant achievement for January 2024, securing a total of 69 Marketing Authorisation Approvals. This success spans across 18 countries, in collaboration with 12 esteemed strategic partners. During this...

On World Cancer Day, Adalvo proudly stands at the forefront of the global battle against cancer. As we commemorate this significant day, we invite you to explore Adalvo's comprehensive Oncology...

As World Cancer Day approaches on Sunday, February 4th, Adalvo reaffirms its commitment to making a meaningful impact in the fight against cancer. With a focus on oncology, Adalvo continues...

Adalvo is pleased to announce the successful DCP submission for Brivaracetam Film-Coated Tablets on Day 1 after the expiry of the Data Exclusivity period, developed in collaboration with one of...

Adalvo is pleased to announce the successful DCP submission for Macitentan 10mg film-coated tablets, developed in collaboration with one of our strategic partners. This product is based on the reference brand Opsumit 10mg film-coated...

Adalvo and ITP are thrilled to announce the successful implementation of SAP S/4HANA, marking the beginning of a promising journey in digital transformation. This collaboration has laid the foundation for a scalable cloud-based...